STIM2

Across TCGA pan-cancer cohorts, STIM2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STIM2 data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher STIM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STIM2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SCLC, THYM, and UCEC are the cancer types where STIM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	48	view →
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	1.000	0.602	<.001	22	view →
LUSC	DFS	Median	II,III,IV	0.163	0.720	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.667	.016	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STIM2–SCLC (OS)

Open the SCLC breakdown →